ライフサイエンスコーパス: calcium channel blocker

1 genous nitric oxide donor), and verapamil (a calcium channel blocker).

2 orable outcomes when randomized to receive a calcium channel blocker.

3 The fourth compound, suloctidil, is a calcium channel blocker.

4 alcium channel blocker or ACE inhibitor plus calcium channel blocker.

5 ist, and 200 nM omega-agatoxin IVA, a P-type calcium channel blocker.

6 concomitantly treated with cyclosporin and a calcium channel blocker.

7 roup, but substituted a beta blocker for the calcium-channel blocker.

8 patients already receiving a beta blocker or calcium-channel blocker.

9 ular block, and those using beta-blockers or calcium channel blockers.

10 e intake of CsA, which might be abrogated by calcium channel blockers.

11 altered in the presence of L-, R- and T-type calcium channel blockers.

12 mpared with patients who have never received calcium channel blockers.

13 ct would be stronger among persons not using calcium channel blockers.

14 phospholipid translocase and is inhibited by calcium channel blockers.

15 um by cobalt and was slowed by more specific calcium channel blockers.

16 rtate (NMDA) receptor antagonist MK 801, and calcium channel blockers.

17 utamate receptor antagonists, and sodium and calcium channel blockers.

18 alcium spikes, blocked by cadmium and L-type calcium channel blockers.

19 nt for differential likelihoods of receiving calcium channel blockers.

20 rdiovascular risks of magnesium sulphate and calcium channel blockers.

21 was activated by voltage and was blocked by calcium channel blockers.

22 potent, selective, brain-penetrating T-type calcium channel blockers.

23 brain penetrant and selective triple T-type calcium channel blockers.

24 ent, selective, and brain-penetrating T-type calcium channel blockers.

25 ement for use of statins, beta-blockers, and calcium channel blockers.

26 d with a beta-blocker or non-dihydropyridine calcium channel blockers.

27 by SOC inhibitors, but not by voltage-gated calcium channel blockers.

28 received verapamil to evaluate the effect of calcium channel blockers.

29 ith sepsis were analyzed, 18.6% of whom used calcium channel blockers.

30 ted a mechanism of action similar to that of calcium channel blockers.

31 ding concurrent use of CYP3A4 inhibitors and calcium-channel blockers.

32 ual variation in SBP was reduced the most by calcium-channel blockers (0.76, 0.67-0.85, p<0.0001).

33 CTs (91%) of diuretics, 5 of 7 RCTs (71%) of calcium channel blockers, 3 of 3 RCTs (100%) of antiplat

34 (-5.76 mm Hg [95% CI -10.28 to -1.23]) or a calcium-channel blocker (-5.13 mm Hg, [-9.47 to -0.79])

35 ngiotensin-receptor blockers, beta-blockers, calcium channel blockers); (5) Most patients with hypert

36 The most commonly used medication class was calcium-channel blockers (55.2%, 55.0-55.4).

37 0.76; 95% confidence interval=0.74-0.78) and calcium channel blockers (adjusted hazard ratio=0.93; 95

38 Overdoses of calcium channel blocker agents result in hyperglycemia,

39 ergic blocker (beta-blocker) alone in 24%, a calcium channel blocker alone in 17%, digoxin alone in 1

40 A calcium channel blocker also mimicked NGF treatment.

41 Additionally, use of calcium channel blocker also shows a significant associa

42 Inhibition of Ca(2+) mobilization with calcium channel blockers also inhibits Ang-2 release.

43 tensin-II-receptor blocker irbesartan or the calcium-channel blocker amlodipine slows the progression

44 zyme inhibitor (ramipril), a dihydropyridine calcium channel blocker (amlodipine) or a beta-blocker (

45 or azithromycin (n = 94,083) while taking a calcium-channel blocker (amlodipine, felodipine, nifedip

46 l 2.5-10 mg/d; n = 436) or a dihydropyridine calcium channel blocker, (amlodipine 5-10 mg/d; n = 217)

47 original trials used 3 different statins, a calcium-channel blocker, an angiotensin-converting enzym

48 For primary prevention, we used aspirin, a calcium-channel blocker, an angiotensin-converting-enzym

49 effects of incident diabetes associated with calcium channel blocker and angiotensin-converting enzym

50 16%, a beta-blocker and digoxin in 14%, or a calcium channel blocker and digoxin in 14% of patients.

51 e depolarization was slightly inhibited by a calcium channel blocker and markedly inhibited by a Na(+

52 It was the first clinically used calcium channel blocker and remains in clinical use, alt

53 ented with a K(ATP) channel opener but not a calcium channel blocker and the other potentially arisin

54 The other 2 agents should include calcium channel blockers and angiotensin-converting enzy

55 f cases, VR-PAH has a pronounced response to calcium channel blockers and better survival than vasodi

56 ltures of human kidney epithelial cells with calcium channel blockers and by lowering extracellular c

57 Calcium channel blockers and calmodulin inhibitors added

58 Calcium channel blockers and calmodulin inhibitors incre

59 Calcium channel blockers and hydrochlorothiazide are imp

60 tients with DM were more commonly prescribed calcium channel blockers and long-acting nitrates at dis

61 e reveals inverse correlation between use of calcium channel blockers and lung cancer diagnosis.

62 Calcium channel blockers and renin-angiotensin system in

63 termine the association between prior use of calcium channel blockers and the outcome of patients adm

64 rug class use between cases and controls for calcium channel blockers and thiazides was noted.

65 For calcium channel blockers and thiazides, the matched odds

66 Diuretics are superior to calcium channel blockers and, at least in the short term

67 The opposite effects of calcium-channel blockers and beta blockers on variabilit

68 nsion, nonsteroidal anti-inflammatory drugs, calcium channel blockers, and alcohol, but not for diabe

69 ent for known antipsychotic drugs, selective calcium channel blockers, and antiepileptics.

70 f defective mitochondria, kinase inhibitors, calcium channel blockers, and approaches that interfere

71 sed by the antiseizure medication phenytoin, calcium channel blockers, and ciclosporin.

72 thmics), versus rate control (beta-blockers, calcium channel blockers, and digoxin) treatment strateg

73 olled in the groups receiving beta-blockers, calcium channel blockers, and digoxin, respectively.

74 blockers, beta-blockers, thiazide diuretics, calcium channel blockers, and metformin.

75 Prostaglandin analogues, calcium channel blockers, and oral corticosteroids have

76 which is structurally related to therapeutic calcium channel blockers, and that a natural coding-regi

77 rate-control treatment with beta-blockers or calcium channel blockers, and the use of beta-blockers w

78 inhibitors, angiotensin II type 1 blockers, calcium channel blockers, and thiazolidinediones have a

79 inhibitors, angiotensin II type 1 blockers, calcium channel blockers, and thiazolidinediones justifi

80 ons were sensitive to membrane potential and calcium channel blockers, and were potentiated by niflum

81 Commonly used medications include calcium channel blockers, angiotensin receptor blockers

82 ated included beta-blockers, ACE inhibitors, calcium channel blockers, angiotensin receptor blockers,

83 Calcium channel blockers are among the most commonly use

84 ce, the roles of gene therapy, hepcidin, and calcium channel blockers are being actively investigated

85 Conversely, the benefits of calcium channel blockers are increasingly recognized.

86 Dihydropyridine calcium channel blockers are unlikely to have a clinical

87 Calcium-channel blockers are grouped under class IV.

88 High doses of calcium-channel blockers are indicated only in the minor

89 included all published trials concluded that calcium-channel blockers are inferior to other classes o

90 Calcium-channel blockers are metabolized by the cytochro

91 beta-Blockers and calcium-channel blockers are more effective than placebo

92 These findings support the use of calcium channel blockers as a strategy to minimize the n

93 he use of thiazide diuretics and long-acting calcium channel blockers as first-line therapy to treat

94 is assay, we identified fendiline, an L-type calcium channel blocker, as a specific inhibitor of K-Ra

95 this study further support an association of calcium channel blockers, as well as thiazides, with CEE

96 angiotensin-converting enzyme inhibitors or calcium channel blockers at least once during the observ

97 use, although it has been eclipsed by other calcium channel blockers because of its short half-life

98 ication (beta = 0.75; P = .04), specifically calcium channel blockers (beta = -1.02; P < .001), was s

99 Polytherapy with a calcium channel blocker, beta-blocker, or angiotensin-co

100 compared with pharmacy records for statins, calcium channel blockers, beta-blockers, and bisphosphon

101 Suppression of VA may be achieved using calcium-channel blockers, beta-adrenergic blockers, and

102 The effects of nitrates, calcium-channel blockers, beta-blockers, and statins on

103 of diabetes, or use of aspirin, statins, or calcium channel blockers between the 2 groups.

104 edium contains nitrendipine, a voltage-gated calcium channel blocker, but fails to occur when applica

105 uld be terminated by nitrendipine, an l-type calcium channel blocker, but not by the Na channel block

106 ivated cation channels but was halved by the calcium channel blocker cadmium and abolished by tetrodo

107 The voltage-gated calcium channel blocker cadmium chloride did not alter t

108 neurons was not altered by the voltage-gated calcium channel blocker cadmium chloride that blocks bot

109 gic mEPSC was unaltered by the voltage-gated calcium channel blocker cadmium, and was abolished by th

110 y tachykinin neuropeptide, voltage-sensitive calcium channel blocker cadmium, or antioxidants DTT and

111 Oscillations were unaffected by the calcium channel blockers cadmium and nickel and by block

112 Experimental studies suggest that calcium channel blockers can improve sepsis outcome.

113 Calcium channel blockers (CCB) are widely prescribed ant

114 gen tension, inhaled nitric oxide (iNO), and calcium channel blockers (CCB) in 10 patients with BPD w

115 Treatment with calcium channel blockers (CCB), proven to be beneficial

116 ptor (MR) antagonist in vitro potency and no calcium channel-blocker (CCB) activity.

117 dult patients with favorable prognosis using calcium-channel blocker (CCB) therapy.

118 ), ACE inhibitor (1618 of 22,941, or 7.05%), calcium-channel blocker (CCB, 2791 of 38,607, or 7.23%),

119 crolimus while controlling for the effect of calcium channel blockers (CCBs) and supragingival plaque

120 Calcium channel blockers (CCBs) are prescribed to patien

121 cancer risk associated with long-term use of calcium channel blockers (CCBs) or angiotensin-convertin

122 The potential of calcium channel blockers (CCBs) to induce gingival enlar

123 Little is known about associations of calcium channel blockers (CCBs) with outcomes in patient

124 iotensin-converting enzyme (ACE) inhibitors, calcium channel blockers (CCBs), alpha-blockers, and ang

125 450 (CYP3A4) pathway, which also metabolizes calcium channel blockers (CCBs).

126 ing-enzyme inhibitors [ACEi], beta blockers, calcium-channel blockers [CCBs], or diuretics) with foll

127 ccepted mechanism of action of nifedipine, a calcium-channel blocker clinically used in patients with

128 Among older adults taking a calcium-channel blocker, concurrent use of clarithromyci

129 Moreover, embryos grown in calcium channel blocker-containing medium had hearts tha

130 Fatty acid loading or calcium channel blockers could decrease myocardial (18)F

131 nd burst firing, and selective triple T-type calcium channel blockers could offer a new way to treat

132 control studies suggest that dihydropyridine calcium channel blockers (DiCCBs) may protect against Pa

133 or stroke, diuretics plus ACE inhibitors or calcium channel blockers did not differ from diuretics p

134 Other classes of L-type calcium channel blockers did not mislocalize K-Ras, sugg

135 trials have failed to show conclusively that calcium-channel blockers differ from other antihypertens

136 ttern, we applied the benzothiazepine L-type calcium channel blocker, diltiazem.

137 Inorganic calcium channel blockers disclosed that these distinct O

138 CE inhibitors, non-ophthalmic beta blockers, calcium channel blockers, diuretics, and angiotensin rec

139 tor blockers, alpha-blockers, beta-blockers, calcium channel blockers, diuretics, nitrates, statins,

140 s to account for the use of beta-blockers or calcium channel blockers during follow-up did not alter

141 Ethosuximide, a T-type calcium channel blocker, eliminated busting in lesioned

142 treatments (eg, nitrates, beta blockers, and calcium-channel blockers), emerging anti-angina treatmen

143 Most calcium channel blockers exhibit state-dependence (i.e.,

144 Autoantibodies, vascular features, use of calcium channel blockers, extent of pulmonary function,

145 (ATP) channel opener pinacidil (n=6) and the calcium channel blocker flunarizine (n=6).

146 X-sensitive sodium currents and a mixture of calcium channel blockers for calcium currents) and ionic

147 Nevertheless, the utility of calcium channel blockers for heart disease is limited be

148 the gabapentinoids for neuropathic pain and calcium channel blockers for otherwise intractable pain

149 coding insect specific sodium, potassium and calcium channel blockers for their ability to improve th

150 Women treated with a diuretic plus a calcium channel blocker had an 85% greater risk of CVD d

151 Voltage-dependent calcium channel blockers had little effect on the initia

152 or responses to ketamine, whereas the L-type calcium-channel blocker had no significant effects on re

153 Nimodipine, an L-type calcium channel blocker has been shown to reduce iron-in

154 Use of calcium channel blockers has been found to improve sepsi

155 We have shown previously that prenylamine, a calcium channel blocker, has potent local anesthetic act

156 As calcium channel blockers have been safely used in clinic

157 ntal studies, and in a few clinical studies, calcium channel blockers have been shown to ameliorate s

158 Consistent with this, many calcium channel blockers have been shown to be neuroprot

159 Oxygen radical scavengers and calcium channel blockers have been shown to enhance func

160 .33; 95% confidence interval, 1.13 to 1.57), calcium channel blockers (HR, 1.57; 95% confidence inter

161 ontrolling anginal symptoms (Dihydropyridine calcium channel blockers if already on a beta-blocking a

162 y on a beta-blocking agent and rate-limiting calcium channel blockers if beta blockers are contraindi

163 data support the use of inotropic agents or calcium channel blockers in heart failure.

164 ective than beta-blockers or dihydropyridine calcium channel blockers in slowing GFR decline.

165 ngiotensin-converting enzyme inhibitors, and calcium channel blockers in the treatment groups was sim

166 rvational data to suggest a central role for calcium channel blockers in the treatment of microvascul

167 tory drugs to 100% for avoiding short-acting calcium-channel blockers in patients with heart failure

168 ished by omitting Na+ or by applying peptide calcium channel blockers, indicating that nAChRs trigger

169 econtamination following a potentially toxic calcium channel blocker ingestion (1D); 2) as first-line

170 We were surprised to discover that calcium channel blockers inhibited TXNIP expression in I

171 re, pretreatment of cells with nifedipine, a calcium channel blocker, inhibited vanadium-induced NFAT

172 hod for developing novel genetically encoded calcium channel blockers inspired by Rem, a small G-prot

173 correlate directly with the severity of the calcium channel blocker intoxication.

174 This study determines whether the use of calcium channel blockers is associated with a decreased

175 The fungal calcium channel blocker KP4 inhibited the [Ca(2+)](c) re

176 leakage were inhibited in RPS2 plants by the calcium channel blocker LaCl(3), highly correlating thes

177 By contrast, the calcium-channel blocker LaCl3 suppressed the increase in

178 of extracellular calcium or addition of the calcium channel blocker lanthanum (0.5 mM) inhibited the

179 otensin II receptor blockers, beta-blockers, calcium channel blockers, loop diuretics, selective sero

180 tudies we have examined the effects of a new calcium channel blocker, LY393615 ((N-Butyl-[5,5-bis-(4-

181 resent studies we have reported that a novel calcium channel blocker, LY393615, with good bioavailabi

182 The long-term use of calcium channel blockers may be protective, but newer ag

183 Moreover, antiepileptics and calcium channel blockers may provide repurposing opportu

184 ng from both a KATP channel activation and a calcium channel blocker mechanism.

185 Amlodipine was the most commonly prescribed calcium-channel blocker (more than 50% of patients).

186 with endothelin receptor antagonist (n=2) or calcium channel blocker (n=1).

187 nsin-converting enzyme inhibitors (n = 437), calcium-channel blockers (n = 223), diuretics (n = 226),

188 reduced by 5-HT, and fully abolished by the calcium channel blocker nickel.

189 Although the L-type voltage-gated calcium channel blocker nifedipine did not suppress calc

190 ed calcium entry blocked DIR, but the L-type calcium channel blocker nifedipine did not.

191 nnel agonist Bay K 8644 and inhibited by the calcium channel blocker nifedipine in a dose-dependent m

192 ATP)) channel opener diazoxide or the l-type calcium channel blocker nifedipine mimicked the effect o

193 of CHO or THP-1 (macrophage) cells with the calcium channel blocker nifedipine prevented 25-hydroxyc

194 The calcium channel blocker nifedipine reduced, and the sarc

195 primary target is another channel, e.g. the calcium channel blocker nifedipine, the sodium channel b

196 First, we observed that the L-type calcium channel blockers nifedipine and verapamil effect

197 ium release, and the presence of impermeable calcium channel blockers nifedipine, SKF96365, or LaCl3,

198 compare the effectiveness and safety of the calcium-channel blocker nifedipine and the oxytocin inhi

199 Oxidation of the calcium-channel blocker nifedipine is measured using UV-

200 ceptor blockers (phentolamine, labetalol), a calcium channel blocker (nifedipine), and splanchnic vas

201 The L-type calcium channel blocker, nifedipine, significantly atten

202 This effect was mimicked by the calcium channel blocker, nifedipine.

203 ory reactivation by the L-type voltage-gated calcium channel blocker nimodipine interferes with the a

204 The L-type calcium channel blockers nimodipine and nifedipine aboli

205 +) but not by Mg(2+) or the classical l-type calcium channel blocker, nitrendipine.

206 uced in patients receiving CsA paralleled by calcium channel blockers nor significantly reduced in pa

207 ination with digoxin, or non-dihydropyridine calcium-channel blockers (not in heart failure) effectiv

208 s study was undertaken to investigate L-type calcium channel blockers of the dihydropyridine class fo

209 oprotective role for centrally acting L-type calcium channel blockers of the dihydropyridine class in

210 Calcium channel blockers of the phenylalkylamine family

211 el of alanine mutants of the insect-specific calcium channel blocker omega-atracotoxin-Hv1a.

212 ed by targeted delivery of the voltage-gated calcium channel blocker omega-conotoxin GVIA.

213 ot suppress calcium oscillations, the N-type calcium channel blocker omega-conotoxin inhibited this s

214 The effects of enzyme inhibitors and calcium channel blockers on the actions of the NO donor

215 ts should continue to take beta-blockers and calcium channel blockers on the day of surgery.

216 ients were either receiving beta-blockers or calcium-channel blockers on follow-up.

217 ffect of nilvadipine, a dihydropyridine-type calcium channel blocker, on Abeta induced vasoconstricti

218 plus either ACE inhibitor, beta-blocker, or calcium channel blocker or ACE inhibitor plus calcium ch

219 population, including those with diabetes, a calcium channel blocker or thiazide-type diuretic is rec

220 oices should be a long-acting diuretic and a calcium-channel blocker or a beta-blocker, respectively.

221 Patients given calcium-channel blockers or alpha blockers had a 65% (ab

222 All randomised controlled trials in which calcium-channel blockers or alpha blockers were used to

223 se all randomised controlled trials in which calcium-channel blockers or alpha blockers were used to

224 Calcium channel blockers (OR = 0.5, 95% CI: 0.2, 0.9) an

225 ]; P = .002), and the use of dihydropyridine calcium channel blockers (OR, 9.24 [95% CI, 1.35-63.23];

226 therapy with an ACE inhibitor, beta-blocker, calcium channel blocker, or diuretic, and 4493 (23%) wer

227 yme inhibitor, angiotensin receptor blocker, calcium channel blocker, or thiazide-type diuretic in th

228 e inhibitors, angiotensin-receptor blockers, calcium channel blockers, or beta blockers) was signific

229 No adequate trials of dexamethasone, calcium channel blockers, or magnesium sulphate have yet

230 of medications classified as beta blockers, calcium channel blockers, or psychotropics.

231 ngiotensin-receptor blockers, beta blockers, calcium-channel blockers, or direct renin inhibitors (pr

232 ngiotensin receptor blockers, beta blockers, calcium channel blockers, other BP medications, aspirin,

233 eding index (P=0.001) and concomitant use of calcium channel blockers (P=0.029); in CsA and Tcr group

234 le sex, diabetes status, insulin use, use of calcium channel blocker, panendoscopic examination, hype

235 no history of CVD, a 2-drug-class regimen of calcium channel blockers plus diuretics was associated w

236 rovide a management approach for adults with calcium channel blocker poisoning.

237 In our primary analyses, we excluded all calcium channel blocker prescriptions 2 years before ind

238 Analyses of some randomised trials show that calcium-channel blockers reduce the risk of stroke more

239 gents, including beta-blockers, nitrates and calcium channel blockers, remain the mainstay in the pre

240 ial treatment of systemic corticosteroid and calcium channel blocker, remarkable improvement was noti

241 Replacement of calcium channel blockers resulted in the largest potenti

242 lcium influx was blocked by the nonselective calcium channel blockers ruthenium red, 1-(beta-[3-(4-me

243 statins, histamine H2-receptor blockers, or calcium-channel blockers seems to prevent Alzheimer's di

244 diabetic mice with cilnidipine, an N-/L-type calcium channel blocker, showed a reduction in albuminur

245 ore severe digital tip ulcers, but they used calcium channel blockers significantly less frequently (

246 ith cyclosporin A and concomitantly taking a calcium channel blocker since transplant were entered in

247 Treatment with the calcium channel blocker SK&F 96365 inhibited translocati

248 ibited by the calcium chelator BAPTA-AM, the calcium channel blocker SK&F 96365, and calpeptin, an in

249 x was also inhibited by omega-agatoxin-TK, a calcium channel blocker specific for Ca(v)2.1 channels.

250 First-generation calcium channel blockers such as verapamil are a widely

251 On subgroup analysis, calcium channel blockers tend to be more beneficial to p

252 veal a universal method for developing novel calcium channel blockers that may be extended to develop

253 gene transfer of Gem functions as a genetic calcium channel blocker, the local application of which

254 In this national cohort study, preadmission calcium channel blocker therapy before sepsis developmen

255 Patients who responded to calcium channel blocker therapy had metabolic profiles s

256 patients showing long-term improvement with calcium channel-blocker therapy.

257 reports about 19 diverse treatments, such as calcium-channel-blocker therapy for coronary artery dise

258 phenylalkylamine (PAA), and it was the first calcium channel blocker to be used clinically.

259 of hearts with diltiazem, a specific L-type calcium channel blocker, to eliminate the involvement of

260 commendations for the stepwise management of calcium channel blocker toxicity.

261 ients with sepsis, of which, 19,742 received calcium channel blocker treatments prior to the admissio

262 The association between calcium channel blocker use and sepsis outcome was deter

263 test the association between dihydropyridine calcium channel blocker use and the time to important mi

264 Prior calcium channel blocker use is associated with reduced m

265 Concurrent calcium channel blocker use minimizes or negates the inv

266 Prior calcium channel blocker use was not associated with chan

267 found no evidence of effect modification by calcium channel blocker use, possibly because of modest

268 ations and to examine effect modification by calcium channel blocker use, using linear regression and

269 t smoking, prior cardiovascular disease, and calcium channel blocker use.

270 ministration of artemether and nimodipine, a calcium channel blocker used to treat postsubarachnoid h

271 nsidering large baseline differences between calcium channel blocker users and nonusers, a propensity

272 hrombin levels, which were less decreased in calcium channel blocker users.

273 ensity-matched cohort (20.2% vs 32.9% in non-calcium channel blockers users; p = 0.009) and in multiv

274 In sharp contrast, the L-type calcium channel blocker verapamil markedly decreased S1P

275 ivo, we administered the clinically approved calcium channel blocker verapamil to obese mice.

276 sed in combination with 2 broadly prescribed calcium channel blockers (verapamil ER and diltiazem ER)

277 Calcium channel blockers (verapamil, lanthanum) can also

278 erindividual variation in SBP was reduced by calcium-channel blockers (VR 0.81, 95% CI 0.76-0.86, p<0

279 Monotherapy with calcium channel blockers vs diuretics was associated wit

280 ratios for diabetes, insulin use and use of calcium channel blocker was 1.133 (1.074, 1.195), 1.414

281 Use of calcium channel blocker was associated with a reduced 30

282 concomitantly treated with cyclosporin and a calcium channel blocker was associated with functional p

283 Prior use of calcium channel blockers was associated with improved 30

284 onferroni correction was applied, the use of calcium channel blockers was most strongly associated wi

285 ribing clarithromycin vs azithromycin with a calcium-channel blocker was associated with a higher ris

286 iew to creating a focally applicable genetic calcium channel blocker, we overexpressed the ras-relate

287 -reported use of statins, beta-blockers, and calcium channel blockers were all 95% or greater.

288 In addition, the effects of potassium and calcium channel blockers were also tested for comparison

289 Statins, beta-blockers, and calcium channel blockers were each reported by over 15%

290 For the prevention of heart failure, calcium channel blockers were inferior and diuretics wer

291 Calcium channel blockers were superior to other drugs fo

292 Nitroglycerin as needed and a beta- or calcium-channel blocker were allowed.

293 t failure is increased in patients receiving calcium channel blockers when compared with those receiv

294 w that long-term treatment with verapamil, a calcium channel blocker with vasodilator properties, can

295 orming alpha1-subunits can be converted into calcium channel blockers with tunable selectivity, kinet

296 Nimodipine is a calcium-channel blocker with specific cerebral vasodilat

297 alpha blockers was 1.54 (1.29-1.85) and for calcium-channel blockers with steroids was 1.90 (1.51-2.

298 rst drug (with or without digoxin), 54% with calcium channel blockers (with or without digoxin), and

299 enzyme (ACE) inhibitor and a dihydropyridine calcium-channel blocker would be more effective in reduc

300 holesterol content can be reversed by AbetaP calcium channel blockers Zn2+ and tromethamine.